|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US4534899A
(en)
|
1981-07-20 |
1985-08-13 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
JP3022967B2
(ja)
|
1985-03-15 |
2000-03-21 |
アンチバイラルズ インコーポレイテッド |
立体規則性ポリヌクレオチド結合ポリマー
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
WO1993001286A2
(en)
|
1991-06-28 |
1993-01-21 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
|
US5521291A
(en)
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
FR2692265B1
(fr)
|
1992-05-25 |
1996-11-08 |
Centre Nat Rech Scient |
Composes biologiquement actifs de type phosphotriesters.
|
|
AU701578B2
(en)
|
1992-08-21 |
1999-02-04 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
DK0690873T3
(da)
|
1993-03-19 |
2003-09-29 |
Univ Johns Hopkins Med |
Vækstdifferentieringsfaktor-8
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
US20030074680A1
(en)
|
1993-03-19 |
2003-04-17 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8
|
|
US5462854A
(en)
|
1993-04-19 |
1995-10-31 |
Beckman Instruments, Inc. |
Inverse linkage oligonucleotides for chemical and enzymatic processes
|
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
CN1123038A
(zh)
|
1993-05-11 |
1996-05-22 |
北卡罗来纳大学查珀尔希尔分校 |
阻止异常剪接的反义寡核苷酸及其使用方法
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US6060456A
(en)
|
1993-11-16 |
2000-05-09 |
Genta Incorporated |
Chimeric oligonucleoside compounds
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
|
TW311927B
(https=)
|
1995-07-11 |
1997-08-01 |
Minnesota Mining & Mfg |
|
|
US7803782B2
(en)
|
2003-05-28 |
2010-09-28 |
Roche Madison Inc. |
Intravenous delivery of polynucleotides to cells in mammalian limb
|
|
ATE330644T1
(de)
|
1995-12-18 |
2006-07-15 |
Angiotech Biomaterials Corp |
Vernetzten polymerisatmassen und verfahren für ihre verwendung
|
|
US6245747B1
(en)
|
1996-03-12 |
2001-06-12 |
The Board Of Regents Of The University Of Nebraska |
Targeted site specific antisense oligodeoxynucleotide delivery method
|
|
AU729643B2
(en)
|
1996-05-01 |
2001-02-08 |
Antivirals Inc. |
Polypeptide conjugates for transporting substances across cell membranes
|
|
IL132941A0
(en)
|
1997-05-21 |
2001-03-19 |
Univ Leland Stanford Junior |
Composition and method for enhancing transport across biological membranes
|
|
US6103466A
(en)
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
|
DE69841139D1
(de)
|
1997-07-14 |
2009-10-22 |
Univ Liege |
Mutationen im myostatingen steigern muskelmasse in säugetieren
|
|
US6133246A
(en)
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6228579B1
(en)
|
1997-11-14 |
2001-05-08 |
San Diego State University Foundation |
Method for identifying microbial proliferation genes
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6172216B1
(en)
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US7094765B1
(en)
|
1999-01-29 |
2006-08-22 |
Avi Biopharma, Inc. |
Antisense restenosis composition and method
|
|
JP2002535015A
(ja)
|
1999-01-29 |
2002-10-22 |
エイブイアイ バイオファーマ， インコーポレイテッド |
標的ｒｎａを検出するための非侵襲性方法
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
|
US6284882B1
(en)
|
1999-06-10 |
2001-09-04 |
Abbott Laboratories |
Myostatin gene promoter and inhibition of activation thereof
|
|
US6617440B1
(en)
|
1999-07-30 |
2003-09-09 |
Pfizer, Inc. |
Myostatin regulatory region, nucleotide sequence determination and methods for its use
|
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
KR20020064915A
(ko)
|
1999-11-29 |
2002-08-10 |
에이브이아이 바이오파마 인코포레이티드 |
안티센스 항박테리아 방법 및 조성물
|
|
WO2001049775A2
(en)
|
2000-01-04 |
2001-07-12 |
Avi Biopharma, Inc. |
Antisense antibacterial cell division composition and method
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
JP2004509604A
(ja)
|
2000-03-28 |
2004-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ｍＲＮＡプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
|
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
|
US6784291B2
(en)
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
AU2001271873A1
(en)
|
2000-07-06 |
2002-01-21 |
Avi Biopharma, Inc. |
Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US20050124566A1
(en)
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
|
AU2002334307A1
(en)
|
2001-09-04 |
2003-03-18 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
|
AU2002342057B2
(en)
|
2001-10-16 |
2009-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
JP2003203451A
(ja)
|
2001-12-28 |
2003-07-18 |
Fujitsu Ltd |
ヘッドスライダ
|
|
KR100464261B1
(ko)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
KR20030084444A
(ko)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
WO2004043978A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
EP1713332A4
(en)
|
2004-01-23 |
2010-08-18 |
Avi Biopharma Inc |
ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
|
|
EP1729793B1
(en)
|
2004-03-02 |
2015-07-22 |
Acceleron Pharma Inc. |
Alk7 and myostatin inhibitors for muscle wasting disorders
|
|
WO2005107447A2
(en)
|
2004-05-11 |
2005-11-17 |
Ingenium Pharmaceuticals Ag |
Methods for the production of improved live stocks and disease models for therapeutic research
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
AU2015203791B2
(en)
|
2005-02-09 |
2017-06-29 |
Sarepta Therapeutics, Inc. |
Antisense composition and method for treating
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
NZ563206A
(en)
|
2005-04-22 |
2009-09-25 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
|
|
NL1031674C2
(nl)
|
2005-04-25 |
2007-04-26 |
Pfizer |
Antilichamen tegen myostatine.
|
|
CA2538208A1
(en)
|
2005-05-04 |
2006-11-04 |
Universite Laval |
Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
|
|
SI2548560T1
(sl)
|
2005-06-23 |
2015-12-31 |
Isis Pharmaceuticals, Inc. |
Sestavki in postopki za moduliranje izrezovanja smn2
|
|
WO2007003216A1
(en)
|
2005-07-06 |
2007-01-11 |
Universidad Autónoma de Madrid |
Anti-ccr7 receptor antibodies for the treatment of cancer
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
US7785834B2
(en)
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
|
KR101789603B1
(ko)
|
2005-11-10 |
2017-11-21 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
|
|
DK2735568T3
(da)
*
|
2006-05-10 |
2017-11-13 |
Sarepta Therapeutics Inc |
Oligonukleotidanaloger med kationiske bindinger mellem underenheder
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
WO2008005019A1
(en)
|
2006-07-07 |
2008-01-10 |
Dale Roderic M K |
Compositions and methods for the treatment of muscle wasting
|
|
US20090264353A1
(en)
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
|
CA2666981A1
(en)
|
2006-10-20 |
2008-05-02 |
Ercole Biotech, Inc. |
Soluble tnf receptors and their use in treatment of disease
|
|
TWI782836B
(zh)
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
CN101889086B
(zh)
|
2007-05-01 |
2014-07-02 |
桑塔里斯制药公司 |
Tnf超家族受体的剪接转换寡聚物，以及它们治疗疾病的用途
|
|
ES2798758T3
(es)
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
EP3443976A1
(en)
*
|
2007-06-29 |
2019-02-20 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
CA2693742A1
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
|
US7935816B2
(en)
|
2007-10-25 |
2011-05-03 |
Gene Tools, Llc |
Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
MX2010004955A
(es)
|
2007-11-15 |
2010-06-30 |
Avi Biopharma Inc |
Metodo de sintesis de oligomeros de morfolina.
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
EP2235034B1
(en)
|
2007-12-28 |
2016-11-23 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
CN101939789B
(zh)
|
2008-01-04 |
2013-07-31 |
Cue声学公司 |
带集成的开关式电源的音频设备
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8236557B2
(en)
|
2008-05-28 |
2012-08-07 |
University Of Missouri-Columbia |
Hybrid-AAV vectors to deliver large gene expression cassette
|
|
SMT202300222T1
(it)
|
2008-08-14 |
2023-09-06 |
Acceleron Pharma Inc |
Trappole di gdf
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN112574988A
(zh)
|
2008-10-24 |
2021-03-30 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
GB0821457D0
(en)
*
|
2008-11-24 |
2008-12-31 |
Trillion Genomics Ltd |
Oligonucleotides
|
|
AU2009335740B2
(en)
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
US20120149756A1
(en)
|
2009-04-10 |
2012-06-14 |
Associatin Institut de Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
WO2010120820A1
(en)
|
2009-04-13 |
2010-10-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing
|
|
CA2759899A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
JP5766179B2
(ja)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
筋肉増殖を増加させるための組成物および方法
|
|
WO2010129406A2
(en)
|
2009-05-04 |
2010-11-11 |
The Johns Hopkins University |
Methods of promoting muscle growth
|
|
PT3305302T
(pt)
|
2009-06-17 |
2018-12-14 |
Biogen Ma Inc |
Composições e métodos de modulação de excisões de smn2 em um sujeito
|
|
LT2499249T
(lt)
|
2009-11-12 |
2018-12-27 |
The University Of Western Australia |
Priešprasmės molekulės ir patologijų gydymo būdai
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
KR20200133284A
(ko)
*
|
2010-05-28 |
2020-11-26 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
RS55610B1
(sr)
|
2010-09-30 |
2017-06-30 |
Nippon Shinyaku Co Ltd |
Derivat morfolino nukleinske kiseline
|
|
EP2672977A1
(en)
|
2011-02-08 |
2013-12-18 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Antisense oligonucleotides
|
|
WO2012150960A1
(en)
*
|
2011-05-05 |
2012-11-08 |
Avi Biopharma, Inc. |
Peptide oligonucleotide conjugates
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
EP2581448B1
(en)
|
2011-10-13 |
2015-01-28 |
Association Institut de Myologie |
Tricyclo-phosphorothioate DNA
|
|
EA202090338A1
(ru)
|
2011-11-18 |
2021-04-30 |
Сарепта Терапьютикс, Инк. |
Функционально-модифицированные олигонуклеотиды и их субъединицы
|
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
|
CN117721110A
(zh)
|
2011-12-28 |
2024-03-19 |
日本新药株式会社 |
反义核酸
|
|
CN112251436A
(zh)
|
2012-01-27 |
2021-01-22 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
CA2894899A1
(en)
|
2012-12-20 |
2014-06-26 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
NZ731587A
(en)
|
2013-03-14 |
2021-07-30 |
Sarepta Therapeutics Inc |
Exon skipping compositions for treating muscular dystrophy
|
|
CA2906812A1
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
|
WO2014172448A2
(en)
|
2013-04-17 |
2014-10-23 |
Anaptysbio, Inc. |
Antibodies directed against activin receptor type ii (actrii)
|
|
JP6618910B2
(ja)
*
|
2013-09-05 |
2019-12-11 |
サレプタ セラピューティクス，インコーポレイテッド |
酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
JP2021026584A
(ja)
|
2019-08-07 |
2021-02-22 |
ｉ Ｓｍａｒｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ株式会社 |
改善対策リコメンドシステム
|